Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.42 |
| ▸ | TFPI | P10646 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nonathymulin SCHEMBL29727660 | 1.00 | OPRL1 (0.42) | OPRL1TFPINMT2NMT1APLNR | |
| SCHEMBL29727699 | 0.96 | OPRL1 (0.43) | OPRL1TFPIAPLNRHCRTR1HCRTR2 | |
| SCHEMBL10744274 | 0.95 | OPRL1 (0.42) | OPRL1TFPINMT2NMT1 | |
| SCHEMBL10741300 | 0.90 | TFPI (0.51) | OPRL1TFPI | |
| SCHEMBL11579956 | 0.89 | KDM1A (0.42) | NMT2NMT1APLNR | |
| SCHEMBL10743964 | 0.87 | TFPI (0.51) | OPRL1TFPI | |
| SCHEMBL7787536 | 0.84 | HDAC3 (0.40) | — | |
| SCHEMBL7787541 | 0.84 | HDAC3 (0.40) | — | |
| SCHEMBL29727639 | 0.84 | HDAC3 (0.42) | NMT2NMT1APLNR | |
| SCHEMBL10740555 | 0.83 | NMT1 (0.50) | OPRL1TFPINMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| EP-4504786-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MiroBio Limited (GB) | 2025-02-12 | — | — | EP | claimed |
| US-12139455-B2 | Polyethylene glycol derivative and use thereof | HANMI PHARM. CO., LTD. (KR) | 2024-11-12 | — | — | US | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| WO-2024030514-A1 | EXTRACELLULAR VESICLE-ASSOCIATED ADENO-ASSOCIATED VIRUS VECTORS FOR INHALED GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-08 | — | — | WO | claimed |
| US-20230416361-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-12-28 | — | — | US | claimed |
| WO-2023196866-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MIROBIO LIMITED (GB) | 2023-10-12 | — | — | WO | claimed |
| US-11738084-B2 | Compositions for transfection of biomolecules into cells | SZATHMARY SUSAN (US) | 2023-08-29 | — | — | US | claimed |
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2023-07-06 | — | — | US | claimed |
| US-11603346-B2 | Polyethylene glycol derivative and use thereof | HANMI PHARM. CO., LTD. (KR) | 2023-03-14 | — | — | US | claimed |
| CN-218131460-U | Vibration mixing device of targeted immune thymosin | 中慈保健品科技开发有限公司 | 2022-12-27 | — | — | CN | claimed |
| EP-4013769-A2 | ZINC ACTIVATED THYMULIN AND METHODS OF PREPARATION AND ADMINISTRATION | Cytolyf Therapeutics LLC (US) | 2022-06-22 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4148886-A | TREATMENT OF AUTOIMMUNE DISEASES | Institute National de la Sante & de la Recherche Medicale (INSERM) (FR) | 1979-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603346-B2 | Polyethylene glycol derivative and use thereof | UGCG, NAPEPLD, CD44 | OPRL1 2442/4885TFPI 3250/4885NMT2 1355/4885 |
| US-12139455-B2 | Polyethylene glycol derivative and use thereof | RPN2, MPDU1, RPN1 | OPRL1 2831/4885TFPI 1138/4885NMT2 2453/4885 |
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | RPN2, MPDU1, RPN1 | OPRL1 2831/4885TFPI 1138/4885NMT2 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.